Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
about
Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.A newly identified derivative of amphotericin B: isolation, structure determination and primary evaluation of the activity and toxicity.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BRecent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments.Clinical hepatotoxicity associated with antifungal agents.Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia.Recommendations for the treatment of fungal pneumonias.The lipid formulations of amphotericin B.Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations.Recent advances in antifungal pharmacotherapy for invasive fungal infections.Characterization of a Polyethylene Glycol-Amphotericin B Conjugate Loaded with Free AMB for Improved Antifungal Efficacy.Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines.The role of fat emulsion therapy in a rodent model of propranolol toxicity: a preliminary studyZygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Management of fungal infections following allogeneic stem cell transplantation.An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.Invasive candidiasis: update on current pharmacotherapy options and future perspectives.In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.Potential Use of Alginate-Based Carriers As Antifungal Delivery SystemVoriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B.Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations.Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2.Cutaneous leishmaniasis in a Japanese returnee from West Africa successfully treated with liposomal amphotericin B.Chronic disseminated Trichosporon asahii infection in a leukemic child.Intralipid ameliorates thiopentone induced respiratory depression in rats: investigative pilot study.Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion.Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations.Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.Intralipid prolongs survival in a rat model of verapamil toxicity.Pharmacology of Systemic Antifungal Agents
P2860
Q30240770-007D35D9-302F-45D3-9D1B-44E4925C7E0BQ33626386-6C2F2959-1F1C-4C90-B862-F8D0EE950176Q33722067-9B8BDC29-4350-4E6A-A0C9-EA0DE688CF04Q34417313-5A9F5B89-4A81-4802-BAA5-6396F624256DQ34546811-66F069A9-4505-495A-A7F3-B99506DC04A0Q34997741-3733DAF0-7931-4C07-A8DB-02B3352A4398Q35183728-FFD605E6-F49B-4ECD-830C-E727A33557AFQ35183734-84B204D7-D5DA-411A-BB62-6A538E691B60Q35547641-52356A6C-B66E-434C-8AB2-1B923712D473Q35917383-34E5D745-0593-4A82-B4CF-D9886E02C145Q35967724-D176AEFC-C7C4-4D3D-9A78-D0E746B4D13CQ36427453-C041EAD1-7EB6-42A2-9493-BE88D2EBA824Q36548386-402802B2-1753-4BAD-8F40-6A693052A1ADQ36573951-4591184A-253D-4F1E-9550-5D61015EED6BQ36658236-1E4387D5-DC85-46E9-AB2F-5D38BE1A76B0Q37202860-6C9EC474-7184-4D4D-9BAE-009A09247DC2Q37807907-B3A9EE0D-F360-4EDB-9EBA-CD3F9F614579Q37810091-A06B6690-B767-48BA-B601-2683D41395DBQ38110850-6480D6E8-5424-4FEF-A3F1-FEFBF379ED06Q38547201-C9E3F01C-4333-475D-B95B-582E5FFFAF1EQ39134282-F936C0F5-6FF8-4513-A99D-4B713C216239Q39196770-03380C23-8B88-4755-ABA4-B4301B0CB713Q40197617-82F1F8AE-F5CB-4E38-A333-D90D79F8EC04Q40440168-CA43DEFB-AFE0-4505-8D82-9C77E27F03DCQ40442249-98204C68-6A79-4579-9CE3-3D1B8CF87B94Q43725878-7E26D11A-21F3-4DA6-A26B-E85E338A9C95Q44043648-9B91A51B-42D6-4610-826F-D9C0CD14870FQ46409429-28C76939-DA6C-4EED-B221-79F83793CDA7Q46436185-026573F6-2D80-4759-BF71-659A9CD2B937Q46497522-336E7E65-F700-4ADB-A947-8E969F53AE13Q46877345-5368AAE2-F30A-4C8E-9C98-30C0B2435A0BQ46911621-C4A6390B-3AD0-45C8-8CA1-C770015D7FADQ57533011-F773FE30-7252-44C4-A25A-DD68239B1DA5
P2860
Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Amphotericin B and its new for ...... al efficacy, and tolerability.
@ast
Amphotericin B and its new for ...... al efficacy, and tolerability.
@en
Amphotericin B and its new for ...... al efficacy, and tolerability.
@nl
type
label
Amphotericin B and its new for ...... al efficacy, and tolerability.
@ast
Amphotericin B and its new for ...... al efficacy, and tolerability.
@en
Amphotericin B and its new for ...... al efficacy, and tolerability.
@nl
prefLabel
Amphotericin B and its new for ...... al efficacy, and tolerability.
@ast
Amphotericin B and its new for ...... al efficacy, and tolerability.
@en
Amphotericin B and its new for ...... al efficacy, and tolerability.
@nl
P2860
P1476
Amphotericin B and its new for ...... cal efficacy, and tolerability
@en
P2093
V Letscher-Bru
P2860
P304
P356
10.1034/J.1399-3062.1999.010406.X
P577
1999-12-01T00:00:00Z